secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001193125-25-082089
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharmaceuticals appoints Theodore R. Schroeder to board, effective April 16, 2025
--------------------------------------------------------------------------------

- Schroeder appointed as Class I director, term expiring at 2026 annual meeting; will serve on audit committee.
- Received option for 35,000 shares and 21,000 RSUs, both vesting over three years; plus cash compensation.
- Former CEO of Nabriva Therapeutics, co-founded Cadence Pharmaceuticals (bought by Mallinckrodt), held senior roles at Elan, Dura, and Bristol-Myers Squibb.
- Board determined Schroeder meets Nasdaq independence standards; no related party transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/0001193125-25-082089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525082089/d943974d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-082089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer